Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Siglec-15 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Siglec-15 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Siglec-15 Products |
| Gene Delivery | Siglec-15 Lentivirus / Promise-ORF Premade Particles Full-length ORF for stable cell lines. Internalization assay ready. |
View Siglec-15 Products |
| Benchmark Ab | Anti-Siglec-15 (NC318 Biosimilar Sequence) Recombinant positive control for blockade assays. |
View Siglec-15 Products |
| Validator | Siglec-15 siRNA Set For knockdown verification and specificity controls. |
View Siglec-15 Products |
| Related Target A | CD47 (Myeloid Checkpoint) Competing 'don't eat me' signal; combination rationale. |
View CD47 Products |
| Related Target B | Siglec-9 Co-expressed on myeloid cells; subfamily selectivity testing essential. |
View Siglec-9 Products |
| Related Target C | PD-L1 Synergistic immune checkpoint for combination therapies. |
View PD-L1 Products |
| Related Target D | VISTA Alternative myeloid checkpoint for overcoming PD-1 resistance. |
View VISTA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Siglec Subfamily Selectivity (CD33/Siglec-3, Siglec-9 cross-reactivity) | Ortholog Panel: Human/Mouse/Cyno Siglec-15 plus Homolog Panel (Siglec-3, Siglec-9) proteins strictly verified by Mass Spec; Sequence Verified. |
| Species Cross-Reactivity for Preclinical Models | Human, Cyno, and Mouse Siglec-15 ECD-Fc variants available with matched glycosylation patterns (HEK293 expressed). |
| Sialic Acid Binding Competition | High-purity ECD-Fc preserves native conformation for glycan-binding assays; Sequence Verified. |
| False Positives in Binding Assays | Validated siRNA included for target-specificity confirmation; Endotoxin Controlled. |
| Lack of Positive Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
Live Siglec-15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Myeloid Checkpoint Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
Siglec-15 represents a next-generation myeloid checkpoint distinct from the CD47-SIRPα axis. It is highly expressed on tumor cells and tumor-associated macrophages (TAMs), especially in PD-L1 negative tumors, offering a non-overlapping mechanism for overcoming resistance. NextCure's NC318 leads Phase I/II trials, with growing interest from biotechs in bispecific formats (PD-L1/Siglec-15). The field is pivoting toward combination immunotherapies and macrophage reprogramming strategies. The target's restricted expression profile (myeloid lineage and osteoclasts) offers a theoretical safety advantage over broader immunosuppressive targets, driving renewed investment in solid tumor indications where TAMs drive resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blockade) | NextCure (NC318), Eisai | NSCLC, HNSCC, CRC, PD-L1 neg solid tumors | Blockade of sialic acid binding (Need high-purity ECD-Fc for glycan competition) |
| Bispecific | Emerging Biotechs (PD-L1/Siglec-15) | Cold Tumors, TAM-rich, Refractory Cancers | Selectivity vs CD33/Siglec-9 (Need Homolog panel); Heterodimer validation (Need cross-reactive Abs) |
| ADC (Emerging) | Preclinical Programs | Myeloid-rich Tumors, NSCLC, Ovarian | Internalization Assay (Need full-length Lentivirus stable lines; high-purity antigens) |
Molecular Differentiation & Assay Strategy
1. Subfamily Selectivity – Critical Differentiation Factor Siglec family (CD33/Siglec-3, Siglec-9, Siglec-10) shares high homology in extracellular Ig-like domains. Off-target binding can cause myeloid cell depletion. Assay: Homolog Panel Binding Assay (Siglec-3, Siglec-9, Siglec-15). TarMart: Mass-spec verified human/cyno/mouse Siglec-15 plus Siglec-3 and Siglec-9 counter-screening proteins, all HEK293 expressed for native glycosylation.
2. Cross-species Reactivity Preclinical toxicology often uses cynomolgus monkey; efficacy studies use mouse. Assay: SPR/BLI kinetic comparison of Cyno/Mouse vs Human affinities. TarMart: ECD-Fc fusion proteins for all three species with consistent glycosylation, avoiding CHO cell artifacts.
3. Blockade Mechanism & Epitope Specificity Antibodies must block Siglec-15 binding to sialylated ligands (e.g., CD44) without excessive internalization (for pure blockade; ADC requires internalization). Assay: Glycan competition assay and pH-dependent internalization assay. TarMart: High-purity ECD-Fc retains native V-set Ig domain conformation; Lentivirus for full-length overexpression cell lines, enabling flow cytometry internalization rate measurement.
4. Safety Assessment (Off-target) Avoid cross-reactivity with neuronally expressed Siglec members (e.g., Siglec-11). Assay: Broad selectivity panel (Siglec-11, Siglec-14, etc.). TarMart: Customizable extended Siglec family protein library plus siRNA validation tools.
Related Target Recommendations
- CD47: Competing 'don't eat me' signal; often studied together with Siglec-15 to overcome myeloid suppression.
- Siglec-9: Co-expressed on macrophages; potential compensatory resistance target.
- PD-L1: Standard combination partner; dual PD-L1/Siglec-15 bispecific development requires dual validation tools.
- VISTA: Alternative myeloid checkpoint for overcoming PD-1 resistance.